Clinical trials
Completed Phase 3 Fallopian Tube Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 5 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AGO Study Group | 3 |
| Alliance for Clinical Trials in Oncology | 3 |
| pharmaand GmbH | 3 |
| Eli Lilly and Company | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Hoffmann-La Roche | 2 |
| ImmunoGen, Inc. | 2 |
| Medical Research Council | 2 |
| National Cancer Institute (NCI) | 2 |
| Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fallopian Tube Neoplasms | 43 |
| Ovarian Neoplasms | 38 |
| Carcinoma, Ovarian Epithelial | 24 |
| Peritoneal Neoplasms | 8 |
| Endometrial Neoplasms | 5 |
| Uterine Cervical Neoplasms | 4 |
| Breast Neoplasms | 3 |
| Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Vaginal Neoplasms | 3 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.